RNLX实时信号 | 通过Getagraph.com最大化利润

出售 115530 min ago

@ $1.190

发出时间: 15 Feb 2024 @ 04:54

回报率: -41.17%

上一信号: Feb 15 - 02:31

上一信号: 购买

回报率: 3.48 %

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Stats
今日成交量	216 840
平均成交量	1.95M
市值	47.76M
EPS	$-0.110 ( 2023-11-14 )
下一个收益日期	( $-0.0800 ) 2024-06-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.780
ATR14	$0.00900 (1.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-24	Icahn School Of Medicine At Mount Sinai	Buy	9 360 374	Ordinary Shares
2023-11-20	Coste Catherine	Buy	95 000	Employee Stock Option (right to buy)
2023-11-20	Levangie Daniel J	Buy	95 000	Employee Stock Option (right to buy)
2023-11-20	Parikh Chirag R.	Buy	95 000	Employee Stock Option (right to buy)
2023-11-20	Mills Christopher	Buy	95 000	Employee Stock Option (right to buy)

INSIDER POWER
84.31
Last 27 transactions
Buy: 12 713 670 \| Sell: 1 641 743

音量相关性

長: -0.35 (neutral)

短: -0.28 (neutral)

Signal:(42.915) Neutral

Renalytix AI plc 相关性

10 最正相关
PUCK	0.925
NVCN	0.921
TWLV	0.92
TWCB	0.92
KSICU	0.919
GXII	0.918
OVID	0.917
UBFO	0.916
TBLA	0.915
KVSA	0.914

10 最负相关
AMGN	-0.943
NAKD	-0.921
CYTO	-0.921
AHPI	-0.913
HCAQ	-0.909
PROC	-0.905
LAWS	-0.905
THMA	-0.896
PCSA	-0.894
LSAQ	-0.892

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Renalytix AI plc 相关性 - 货币/商品

-0.29
( neutral )

-0.07
( neutral )

0.00
( neutral )

-0.34
( neutral )

0.42
( neutral )

0.36
( neutral )

Renalytix AI plc 财务报表

Annual	2023
营收:	$3.40M
毛利润:	$701 000 (20.60 %)
EPS:	$-1.120

FY	2023
营收:	$3.40M
毛利润:	$701 000 (20.60 %)
EPS:	$-1.120

FY	2022
营收:	$2.97M
毛利润:	$918 000 (30.91 %)
EPS:	$-1.560

FY	2021
营收:	$1.49M
毛利润:	$633 000 (42.45 %)
EPS:	$-0.860

Financial Reports:

No articles found.

Renalytix AI plc

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.